Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Rangering i aksjer #6354
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Aksjekurs
$33.00
Markedsverdi
$2.08B
Endring (1 dag)
-0.12%
Endring (1 år)
97.49%
Land
US
Handel Zenas BioPharma, Inc. (ZBIO)

Kategori

EPS for Zenas BioPharma, Inc. (ZBIO)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Zenas BioPharma, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Zenas BioPharma, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH